# Taiho Pharmaceutical Co., Ltd. clinical trials: 43 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 43 trials with Taiho Pharmaceutical Co., Ltd. as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Taiho Pharmaceutical Co., Ltd.: 43 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/taiho-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 43
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 17, 2026 | NCT07710885 | Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer | Taiho Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Biliary Tract Cancer | 784 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710885) |
| January 20, 2023 | NCT05691660 | A Study of TAS3731 in Healthy Adults | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Adult Males | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05691660) |
| November 18, 2022 | NCT05621447 | A Mass Balance Study of \[14C\] TAS-303 in Healthy Adult Male Subjects | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Male Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05621447) |
| April 19, 2022 | NCT05335499 | A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria | Taiho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Chronic Spontaneous Urticaria | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05335499) |
| February 18, 2022 | NCT05245968 | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Gastrointestinal Stromal Tumors | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05245968) |
| August 11, 2021 | NCT04999761 | AB122 Platform Study | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer... | 917 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04999761) |
| April 1, 2021 | NCT04825431 | Mass Balance Study of \[14C\] TAS-205 in Healthy Volunteers | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Male Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04825431) |
| December 24, 2020 | NCT04683250 | Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities | Taiho Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04683250) |
| October 29, 2020 | NCT04608110 | A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Myelodysplastic Syndrome (MDS) | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04608110) |
| October 14, 2020 | NCT04587908 | A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD） | Taiho Pharmaceutical Co., Ltd. | Phase 3 | Completed | Duchenne Muscular Dystrophy | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04587908) |
| August 13, 2020 | NCT04512053 | A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence | Taiho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Stress Urinary Incontinence | 231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04512053) |
| July 30, 2018 | NCT03605251 | Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis. | Taiho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Rheumatoid Arthritis | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03605251) |
| June 5, 2017 | NCT03175029 | Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. | Taiho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Detrusor Underactivity, Overactive Bladder | 195 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03175029) |
| September 20, 2016 | NCT02906683 | Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence | Taiho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Stress Urinary Incontinence | 337 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02906683) |
| April 26, 2016 | NCT02752048 | A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy | Taiho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Duchenne Muscular Dystrophy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02752048) |
| September 29, 2015 | NCT02562807 | A Study of TAS-303 in Female Patients With Stress Urinary Incontinence | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Stress Urinary Incontinence | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02562807) |
| December 23, 2014 | NCT02322593 | Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer | Taiho Pharmaceutical Co., Ltd. | Phase 3 | Completed | Gastric Cancer | 711 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02322593) |
| October 10, 2014 | NCT02261532 | A Phase I Study of TAS-102 in Solid Tumors | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Advanced or Metastatic Solid Tumors | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02261532) |
| September 22, 2014 | NCT02246478 | A Study of TAS-205 for Duchenne Muscular Dystrophy | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Duchenne Muscular Dystrophy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02246478) |
| October 8, 2013 | NCT01955837 | Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia | Taiho Pharmaceutical Co., Ltd. | Phase 3 | Completed | Colorectal Cancer | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01955837) |
| June 4, 2012 | NCT01610479 | A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors | Taiho Pharmaceutical Co., Ltd. | Phase 1 | Completed | Advanced Solid Tumors | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01610479) |
| November 4, 2011 | NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma | Taiho Pharmaceutical Co., Ltd. | Phase 3 | Terminated | Hepatocellular Carcinoma | 888 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01465464) |
| May 1, 2009 | NCT00891332 | Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer | Taiho Pharmaceutical Co., Ltd. | Phase 2 | Completed | Colorectal Cancer | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00891332) |
| January 16, 2009 | NCT00824161 | Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer | Taiho Pharmaceutical Co., Ltd. | Phase 2 | Terminated | Advanced Colorectal Cancer | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00824161) |
| November 3, 2008 | NCT00784290 | Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma | Taiho Pharmaceutical Co., Ltd. | Phase 1/2 | Completed | Hepatocellular Carcinoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00784290) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 2 |
| Phase 2 | 14 |
| Phase 2/3 | 1 |
| Phase 3 | 16 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Recruiting | 4 |
| Terminated | 3 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Colorectal Neoplasms | 8 |
| Stomach Neoplasms | 7 |
| Lower Urinary Tract Symptoms | 4 |
| Muscular Dystrophy, Duchenne | 3 |
| Urinary Incontinence, Stress | 3 |
| Urinary Incontinence | 3 |
| Carcinoma, Hepatocellular | 2 |
| Biliary Tract Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Breast Neoplasms | 2 |
| Colonic Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Acrocephalosyndactylia | 1 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 1 |
| Myelodysplastic Syndromes | 1 |
| Gastrointestinal Stromal Tumors | 1 |
| Gastroesophageal Reflux | 1 |
| Esophagitis, Peptic | 1 |
| Vomiting | 1 |
| Nausea | 1 |
| Arthritis, Rheumatoid | 1 |
| Urinary Bladder, Underactive | 1 |
| Urinary Bladder, Overactive | 1 |
| Chronic Urticaria | 1 |
| Uterine Cervical Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [International fusion restaurants in the United States](https://specstream.ai/data/businesses/international-fusion-restaurants/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
- [Electric utilities in the United States](https://specstream.ai/data/businesses/electric-utilities/united-states)
- [Plastic injection molders in the United States](https://specstream.ai/data/businesses/plastic-injection-molders/united-states)
